X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs AUROBINDO PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER AUROBINDO PHARMA PFIZER/
AUROBINDO PHARMA
 
P/E (TTM) x 34.7 18.1 191.4% View Chart
P/BV x 5.1 4.6 111.9% View Chart
Dividend Yield % 0.7 0.3 195.2%  

Financials

 PFIZER   AUROBINDO PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
AUROBINDO PHARMA
Mar-17
PFIZER/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,365895 264.2%   
Low Rs1,625622 261.3%   
Sales per share (Unadj.) Rs430.3254.6 169.0%  
Earnings per share (Unadj.) Rs78.739.3 200.4%  
Cash flow per share (Unadj.) Rs93.246.6 200.1%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %1.00.3 304.2%  
Book value per share (Unadj.) Rs586.5160.0 366.6%  
Shares outstanding (eoy) m45.75585.88 7.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.63.0 155.6%   
Avg P/E ratio x25.319.3 131.3%  
P/CF ratio (eoy) x21.416.3 131.5%  
Price / Book Value ratio x3.44.7 71.7%  
Dividend payout %25.46.4 399.2%   
Avg Mkt Cap Rs m91,271444,390 20.5%   
No. of employees `0002.614.0 18.8%   
Total wages/salary Rs m3,14317,678 17.8%   
Avg. sales/employee Rs Th7,484.810,667.8 70.2%   
Avg. wages/employee Rs Th1,195.01,264.3 94.5%   
Avg. net profit/employee Rs Th1,369.11,645.8 83.2%   
INCOME DATA
Net Sales Rs m19,685149,157 13.2%  
Other income Rs m1,1431,159 98.6%   
Total revenues Rs m20,828150,316 13.9%   
Gross profit Rs m5,00334,343 14.6%  
Depreciation Rs m6634,276 15.5%   
Interest Rs m4667 0.6%   
Profit before tax Rs m5,47930,558 17.9%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8787,597 24.7%   
Profit after tax Rs m3,60123,012 15.6%  
Gross profit margin %25.423.0 110.4%  
Effective tax rate %34.324.9 137.9%   
Net profit margin %18.315.4 118.6%  
BALANCE SHEET DATA
Current assets Rs m24,16792,062 26.3%   
Current liabilities Rs m9,54466,223 14.4%   
Net working cap to sales %74.317.3 428.8%  
Current ratio x2.51.4 182.1%  
Inventory Days Days55106 52.0%  
Debtors Days Days2968 42.4%  
Net fixed assets Rs m9,51462,919 15.1%   
Share capital Rs m458586 78.1%   
"Free" reserves Rs m26,37593,133 28.3%   
Net worth Rs m26,83293,719 28.6%   
Long term debt Rs m251,814 1.4%   
Total assets Rs m36,900162,494 22.7%  
Interest coverage x1,305.546.8 2,789.6%   
Debt to equity ratio x00 4.8%  
Sales to assets ratio x0.50.9 58.1%   
Return on assets %9.814.6 67.0%  
Return on equity %13.424.6 54.7%  
Return on capital %20.432.7 62.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2275,838 0.0%   
Fx outflow Rs m1,48930,224 4.9%   
Net fx Rs m-1,46645,613 -3.2%   
CASH FLOW
From Operations Rs m3,31832,786 10.1%  
From Investments Rs m-2,383-17,870 13.3%  
From Financial Activity Rs m-1,104-19,153 5.8%  
Net Cashflow Rs m-169-4,239 4.0%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 8.0 94.3%  
FIIs % 4.9 27.7 17.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.2 232.4%  
Shareholders   85,207 69,601 122.4%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

GLENMARK PHARMA Plunges by 5%; BSE HEALTHCARE Index Down 2.7% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

GLENMARK PHARMA share price has plunged by 5% and its current market price is Rs 658. The BSE HEALTHCARE is down by 2.7%. The top gainers in the BSE HEALTHCARE Index are IPCA LABS (up 1.3%) and J.B.CHEMICALS (up 1.1%). The top losers are GLENMARK PHARMA (down 5.0%) and PFIZER (down 5.9%).

WOCKHARDT LTD. Plunges by 5%; BSE HEALTHCARE Index Down 1.9% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

WOCKHARDT LTD. share price has plunged by 5% and its current market price is Rs 588. The BSE HEALTHCARE is down by 1.9%. The top gainers in the BSE HEALTHCARE Index are BLISS GVS PHARMA (up 1.0%) and THYROCARE TECHNOLOGIES (up 1.0%). The top losers are WOCKHARDT LTD. (down 5.0%) and PFIZER (down 6.1%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 24, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS